active surveillance in favorable intermediate-risk prostate cancer
Published 2 years ago • 15K plays • Length 11:13Download video MP4
Download video MP3
Similar videos
-
9:15
point-counterpoint: active surveillance for intermediate-risk prostate cancer - pro
-
9:59
point-counterpoint: active surveillance for intermediate-risk prostate cancer - con
-
50:02
active surveillance for favourable risk prostate cancer
-
18:14
active surveillance: intermediate disease and high-volume grade group 1 prostate cancer
-
1:42
active surveillance or intervention in intermediate-risk prostate cancer
-
20:50
active surveillance 2021 - from bench to bedside
-
14:29
active surveillance at johns hopkins: update 2015
-
12:19
active surveillance 2022: who qualifies, who does not and how should it be monitored
-
20:23
active surveillance criteria and follow-up protocol
-
9:14
prostate cancer active surveillance in 2019
-
4:12
active surveillance in localized prostate cancer
-
20:44
active surveillance 2021 (part 3) - patient selection, monitoring, and innocuous interventions
-
25:24
active surveillance in 2021 part 2: imaging and biomarkers
-
23:37
active surveillance who is the right patient and what is the right protocol
-
1:58
integrated diagnostics and patient selection for active surveillance and treatment
-
20:39
active surveillance or: shrinking the gray zone
-
7:22
active surveillance in intermediate-risk prostate cancer
-
17:31
debate: surgery vs. brachytherapy for intermediate and high-risk prostate cancer– brachytherapy
-
18:53
focal therapy for men with intermediate risk prostate cancer